HER2 testing, while widely implemented for breast and gastric cancers, is sorely lacking in standardization and implementation for other cancers, even with mounting evidence of its potential clinical relevance.
This award will provide funding, up to $120,000.00 USD, supporting early-career investigators in conducting quantitative pathology research to optimize and validate HER2 IHC assay use across solid tumors beyond breast and gastric cancer. The funded project(s) will aim to generate critical evidence to guide consistent and accurate patient selection for anti-HER2 ADC therapies, as well as to assess the clinical utility of HER2 testing in tumor types where standardized protocols are currently lacking.
HER2 testing, while widely implemented for breast and gastric cancers, is sorely lacking in standardization and implementation for other cancers, even with mounting evidence of its potential clinical relevance. Three priority areas have been identified that would be greatly impacted by continued research. While not preferred, researchers may select one or more research areas for their project.